Molbio Diagnostics Eyes ₹940 Crore Through IPO for Growth and Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aimed at raising ₹940 crore. The company plans to use ₹200 crore from a fresh issue to boost its capital expenditures, while an additional ₹740 crore will be generated through an offer for sale, effectively reducing the promoter group's stake from 46.6% to 43%.

Expanding Global Reach with Strategic Investments

Established in 2000, Molbio Diagnostics has carved out a niche in the diagnostics market, offering solutions for both infectious and non-communicable diseases. The company's innovative 'Truenat' platform, a portable diagnostics system, has been particularly impactful in resource-constrained settings, delivering accurate results within an hour. The company operates six manufacturing facilities across India and extends its services to over 90 countries, partnering with government health programs, diagnostic labs, hospitals, and international healthcare organizations.

Molbio's financial growth has been robust, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. Net profits have also seen a significant rise of 40.2% annually, reaching ₹164.1 crore. The company's key clients, which include government and international aid agencies, account for over four-fifths of its revenue, highlighting a potential risk of customer concentration.

Financial Performance and Market Position

Molbio's financial indicators show promising trends, with EBITDA increasing by 33.2% to ₹328.2 crore over the same period. The EBITDA margin improved to 22.6% in FY26, up from 22% in FY24. The company's financial health is further underscored by a 41.7% year-on-year revenue jump in FY26, alongside a 27.9% rise in EBITDA and an 18.4% growth in net profit.

The IPO positions Molbio at a price-earnings (P/E) multiple of up to 57, which is in line with other healthcare diagnostics and medical device companies, such as Poly Medicure and Dr. Lal PathLabs, whose P/E multiples range from 54 to 81. Despite the absence of directly comparable listed peers in India, Molbio's strategic focus and financial metrics offer a compelling case for investors with a high-risk appetite.

Potential for Long-Term Growth

Molbio's strategic initiatives and robust financial performance position it well for long-term growth. Nearly 74% of its revenue is derived from the sale of test kits, with a significant portion—70%—coming from tuberculosis diagnostic test kits. With ongoing investments in research and development, as well as strategic collaborations, Molbio aims to expand its portfolio of over 30 disease diagnostics and enhance its offerings in radiology, digital pathology, and breast health screening.

As Molbio Diagnostics steps into the public market, its focus on capital expansion and global market penetration presents a promising opportunity for investors willing to navigate the inherent risks associated with the diagnostics sector.